U.S. markets closed
  • S&P 500

    3,870.29
    -31.53 (-0.81%)
     
  • Dow 30

    31,391.52
    -143.99 (-0.46%)
     
  • Nasdaq

    13,358.79
    -230.04 (-1.69%)
     
  • Russell 2000

    2,231.51
    -43.81 (-1.93%)
     
  • Crude Oil

    59.62
    -1.02 (-1.68%)
     
  • Gold

    1,733.30
    +10.30 (+0.60%)
     
  • Silver

    26.83
    +0.15 (+0.57%)
     
  • EUR/USD

    1.2092
    +0.0032 (+0.27%)
     
  • 10-Yr Bond

    1.4150
    -0.0310 (-2.14%)
     
  • GBP/USD

    1.3957
    +0.0037 (+0.26%)
     
  • USD/JPY

    106.7340
    +0.0040 (+0.00%)
     
  • BTC-USD

    47,809.80
    -843.38 (-1.73%)
     
  • CMC Crypto 200

    955.94
    -30.71 (-3.11%)
     
  • FTSE 100

    6,613.75
    +25.22 (+0.38%)
     
  • Nikkei 225

    29,408.17
    -255.33 (-0.86%)
     

DISCLOSURE UNDER RULE 8.1(a) AND (b)(i) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

  • Oops!
    Something went wrong.
    Please try again later.
Osmotica Holdings US LLC
·3 min read
  • Oops!
    Something went wrong.
    Please try again later.

BRIDGEWATER, N.J., Feb. 01, 2021 (GLOBE NEWSWIRE) --

Ap9

APPENDIX 3
DISCLOSURE
FORMS

FORM 8.1(a)&(b)(i)
AMENDMENT

The Form 8.1(a) dealings disclosure announcement made on January 27, 2020 contained a typographical error in that it referred to dealings in 'relevant securities' by Gregory L. Cowan, when it ought to have referred to dealings by Fred Weiss. This typographical error has now been corrected.

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 8.1(a) AND (b)(i) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

DEALINGS BY OFFERORS, OFFEREES OR PARTIES ACTING IN CONCERT WITH THEM FOR THEMSELVES OR FOR DISCRETIONARY CLIENTS

1. KEY INFORMATION

Name of person dealing (Note 1)

Fred Weiss

Company dealt in

Osmotica Pharmaceuticals plc

Class of relevant security to which the dealings being disclosed relate (Note 2)

Ordinary Shares of US$0.01 each (Ordinary Shares)

Date of dealing

January 27, 2021

2. INTERESTS AND SHORT POSITIONS

(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)

Long

Short

Number

(%)

Number

(%)

(1) Relevant securities

Ordinary Shares: 31,183 (0.05%)

N/A

(2) Derivatives (other than options)

N/A

N/A

(3) Options and agreements to purchase/sell

Restricted stock units (RSUs) pursuant to the Osmotica Pharmaceuticals plc 2018 Incentive Plan (the Plan): 50,185 (0.08%)

N/A

Total

81,368 (0.13%)

N/A

(b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)

Class of relevant security:

Long

Short

Number

(%)

Number

(%)

(1) Relevant securities

N/A

N/A



(2) Derivatives (other than options)

N/A

N/A



(3) Options and agreements to purchase/sell



N/A

N/A

Total

N/A

N/A

Ap10

3. DEALINGS (Note 4)

(a) Purchases and sales

Purchase/sale

Number of relevant securities

Price per unit (Note 5)

N/A

N/A

N/A

(b) Derivatives transactions (other than options transactions)

Product name,

e.g. CFD

Nature of transaction

(Note 6)

Number of relevant securities

(Note 7)

Price per unit

(Note 5)

N/A

N/A

N/A

N/A

(c) Options transactions in respect of existing relevant securities

(i) Writing, selling, purchasing or varying

Product name,
e.g. call option

Writing, selling, purchasing, varying etc.

Number of securities to which the option relates (Note 7)

Exercise price

Type, e.g. American, European etc.

Expiry date

Option money paid/received per unit (Note 5)

N/A

N/A

N/A

N/A

N/A

N/A

N/A

(ii) Exercising

Product name,

e.g. call option

Number of securities

Exercise price per unit (Note 5)

N/A

N/A

N/A

(d) Other dealings (including transactions in respect of new securities) (Note 4)

Nature of transaction

(Note 8)

Details

Price per unit

(if applicable) (Note 5)

Vesting of RSUs pursuant to the Plan

5,962 ordinary shares issued following the vesting of RSUs pursuant to the Plan

N/A

Ap11

4. OTHER INFORMATION

Agreements, arrangements or understandings relating to options or derivatives

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.

N/A

Is a Supplemental Form 8 attached? (Note 9) NO

Date of disclosure

February 1, 2021

Contact name

Lisa M. Wilson

Telephone number

+ 1 212-452-2793

Name of offeree/offeror with which acting in concert

Osmotica Pharmaceuticals plc

Specify category and nature of acting in concert status

Director